Autism Spectrum Disorder (ASD) Clinical Trial
Official title:
A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 Weeks Discontinuation Period After Treatment Stop.
The purpose of this study was to evaluate the efficacy and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.
The present study (CL3-95008-001) was performed in children and adolescents from 7 to less than 18 years old presenting with ASD. A 6-month double-blind treatment period was performed in which efficacy and safety of bumetanide 0.5mg BID were assessed versus placebo. This double-blind period was followed by a 6-month open label treatment period of bumetanide 0.5mg BID in which long term safety was evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05182697 -
SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
| Completed |
NCT02803801 -
Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers
|
N/A | |
| Recruiting |
NCT04376151 -
Guided ACT and for Adults With ASD
|
N/A | |
| Terminated |
NCT03715153 -
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
|
Phase 3 | |
| Terminated |
NCT01592773 -
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
| Withdrawn |
NCT01395953 -
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
|
Phase 2 | |
| Terminated |
NCT01248130 -
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
|
Phase 2 | |
| Completed |
NCT04860986 -
A Repeatability and Reproducibility Study of the EarliPoint™ Device
|
||
| Completed |
NCT04299464 -
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
| Recruiting |
NCT03392870 -
Evaluation of a Clinical Transitional Program in Autism
|
N/A | |
| Completed |
NCT01592786 -
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
|
Phase 2 | |
| Enrolling by invitation |
NCT05187377 -
A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
|
Phase 2 | |
| Completed |
NCT04631432 -
Choice Switching and Autism
|
||
| Recruiting |
NCT04578756 -
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
|
Phase 3 | |
| Recruiting |
NCT06443320 -
Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders
|
N/A | |
| Completed |
NCT02037022 -
Pivotal Response Treatment Package for Young Children With Autism
|
N/A | |
| Completed |
NCT01854346 -
Social Skills Group Training ("KONTAKT") for Children and Adolescent With High-functioning Autism Spectrum Disorders
|
N/A | |
| Active, not recruiting |
NCT04895215 -
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
|
Phase 2 | |
| Active, not recruiting |
NCT03426826 -
The Gut-Brain Study
|
Phase 1 | |
| Completed |
NCT02384486 -
Efficacy of Training Programme to Reduce Stress
|
N/A |